Abstract
In vivo treatment causes permanent changes to a tumor’s drug response profile. A, Experimental framework of in vivo and ex vivo drug response profiling. B, High-throughput drug screening data of dissociated PDTX cells. AUC plots display the response of each tumor to drugs tested ex vivo. Color indicates the in vivo treatment to which each tumor was previously exposed. C, Dose–response curves of models 1040 (top) and 1141 (bottom) to olaparib and BMN-673. Plots compare the untreated PDTX tumors (black) to those previously treated in vivo with CT (red). D, Experimental framework to test alternative sequencing strategies of CT and olaparib in vivo using model 1040. Untreated PDTX tumors and those previously treated with CT or olaparib were each passaged into three cohorts of mice. These mice were left untreated or subsequently exposed to CT or olaparib. E, Estimated mean tumor growth for each experimental group. Panels display previous treatment groups (first-line treatment), and lines within each panel display the cohort of second-line treatment. F, Estimated log-daily growth rate of PDTX tumors, as predicted by the linear mixed models. Column panels display previous treatment groups (first-line treatment), and lines within each panel display the cohort of second-line treatment. G, Predicted tumor (log) volume at treatment end of each cohort treated sequentially with no treatment, CT, or olaparib based on the linear mixed models. Panels display previous treatment groups (first-line treatment), and boxes within each panel display the cohort of second-line treatment.